Xu Li
Xu Li has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Maikun Teng
University of Science and Technology of China
52 shared publications Liwen Niu
Hefei National Laboratory for Physical Sciences at Microscale, Innovation Centre for Cell Signalling Network, School of Life Science, University of Science and Technology of China, Hefei, Anhui 230026, People's Republic of China
31 shared publicationsMaikun Teng
Ministry of Education Key Laboratory for Membraneless Organelles & Cellular Dynamics, Biomedical Sciences and Health Laboratory of Anhui Province, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, P.R. China
23 shared publicationsYuwei Zhu
Hefei National Laboratory for Physical Sciences at Microscale, Innovation Center for Cell Signaling Networks, School of Life Science, University of Science and Technology of China, Hefei, Anhui, 230026, People's Republic of China
14 shared publications- Liwen Niu
MOE Key Laboratory for Membraneless Organelles and Cellular Dynamics, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
10 shared publications Hong Wang
School of Life Sciences University of Science and Technology of China, Hefei Anhui People's Republic of China
8 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
PDF file, 50KB, Surrobody Structure.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
PDF file, 50KB, Surrobody Structure.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
PDF file, 50KB, Surrobody Structure.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ErbB3 Inhibitory Surrobodies Inhibit Tumor Cell Proliferation In Vitro and In Vivo
PDF file, 50KB, Surrobody Structure.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
Supplementary Figure 1 from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
Supplementary Figure 1 from SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome
- Open Access
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Data from MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity
Although aberrant microRNA (miRNA) expressions have been observed in different types of cancer, their pathophysiologic role and their relevance to tumorigenesis are still largely unknown. In this study, we first evaluated the expression of 308 miRNAs in human hepatocellular carcinoma (HCC) and normal hepatic tissues and identified 29 differentially expressed miRNAs in HCC tissues. miR-101, a significantly down-regulated miRNA, was further studied in greater detail because the signal pathway(s) regulated by miR-101 and the role of miR-101 in tumorigenesis have not yet been elucidated. Interestingly, decreased expression of miR-101 was found in all six hepatoma cell lines examined and in as high as 94.1% of HCC tissues, compared with their nontumor counterparts. Furthermore, ectopic expression of miR-101 dramatically suppressed the ability of hepatoma cells to form colonies in vitro and to develop tumors in nude mice. We also found that miR-101 could sensitize hepatoma cell lines to both serum starvation– and chemotherapeutic drug–induced apoptosis. Further investigation revealed that miR-101 significantly repressed the expression of luciferase carrying the 3′-untranslated region of Mcl-1 and reduced the endogenous protein level of Mcl-1, whereas the miR-101 inhibitor obviously up-regulated Mcl-1 expression and inhibited cell apoptosis. Moreover, silencing of Mcl-1 phenocopied the effect of miR-101 and forced expression of Mcl-1 could reverse the proapoptotic effect of miR-101. These results indicate that miR-101 may exert its proapoptotic function via targeting Mcl-1. Taken together, our data suggest an important role of miR-101 in the molecular etiology of cancer and implicate the potential application of miR-101 in cancer therapy. [Cancer Res 2009;69(3):1135–42]
- 30 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity
Although aberrant microRNA (miRNA) expressions have been observed in different types of cancer, their pathophysiologic role and their relevance to tumorigenesis are still largely unknown. In this study, we first evaluated the expression of 308 miRNAs in human hepatocellular carcinoma (HCC) and normal hepatic tissues and identified 29 differentially expressed miRNAs in HCC tissues. miR-101, a significantly down-regulated miRNA, was further studied in greater detail because the signal pathway(s) regulated by miR-101 and the role of miR-101 in tumorigenesis have not yet been elucidated. Interestingly, decreased expression of miR-101 was found in all six hepatoma cell lines examined and in as high as 94.1% of HCC tissues, compared with their nontumor counterparts. Furthermore, ectopic expression of miR-101 dramatically suppressed the ability of hepatoma cells to form colonies in vitro and to develop tumors in nude mice. We also found that miR-101 could sensitize hepatoma cell lines to both serum starvation– and chemotherapeutic drug–induced apoptosis. Further investigation revealed that miR-101 significantly repressed the expression of luciferase carrying the 3′-untranslated region of Mcl-1 and reduced the endogenous protein level of Mcl-1, whereas the miR-101 inhibitor obviously up-regulated Mcl-1 expression and inhibited cell apoptosis. Moreover, silencing of Mcl-1 phenocopied the effect of miR-101 and forced expression of Mcl-1 could reverse the proapoptotic effect of miR-101. These results indicate that miR-101 may exert its proapoptotic function via targeting Mcl-1. Taken together, our data suggest an important role of miR-101 in the molecular etiology of cancer and implicate the potential application of miR-101 in cancer therapy. [Cancer Res 2009;69(3):1135–42]
- Open Access
- 24 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-10
Structural basis of the ligand binding and signaling mechanism of melatonin receptors
Melatonin receptors (MT1and MT2in humans) are family A G protein–coupled receptors that respond to the neurohormone melatonin to regulate circadian rhythm and sleep. Numerous efforts have been made to develop drugs targeting melatonin receptors for the treatment of insomnia, circadian rhythm disorder, and cancer. However, designing subtype-selective melatonergic drugs remains challenging. Here, we report the cryo-EM structures of the MT1–Gisignaling complex with 2-iodomelatonin and ramelteon and the MT2–Gisignaling complex with ramelteon. These structures, together with the reported functional data, reveal that although MT1and MT2possess highly similar orthosteric ligand-binding pockets, they also display distinctive features that could be targeted to design subtype-selective drugs. The unique structural motifs in MT1and MT2mediate structural rearrangements with a particularly wide opening on the cytoplasmic side. Giis engaged in the receptor core shared by MT1and MT2and presents a conformation deviating from those in other Gicomplexes. Together, our results provide new clues for designing melatonergic drugs and further insights into understanding the G protein coupling mechanism.
- 24 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-10
Open AccessStructural basis of the ligand binding and signaling mechanism of melatonin receptors
Melatonin receptors (MT1and MT2in humans) are family A G protein–coupled receptors that respond to the neurohormone melatonin to regulate circadian rhythm and sleep. Numerous efforts have been made to develop drugs targeting melatonin receptors for the treatment of insomnia, circadian rhythm disorder, and cancer. However, designing subtype-selective melatonergic drugs remains challenging. Here, we report the cryo-EM structures of the MT1–Gisignaling complex with 2-iodomelatonin and ramelteon and the MT2–Gisignaling complex with ramelteon. These structures, together with the reported functional data, reveal that although MT1and MT2possess highly similar orthosteric ligand-binding pockets, they also display distinctive features that could be targeted to design subtype-selective drugs. The unique structural motifs in MT1and MT2mediate structural rearrangements with a particularly wide opening on the cytoplasmic side. Giis engaged in the receptor core shared by MT1and MT2and presents a conformation deviating from those in other Gicomplexes. Together, our results provide new clues for designing melatonergic drugs and further insights into understanding the G protein coupling mechanism.
- Open Access
- 6 May 2021
- Published by Wiley in The FEBS Journal
- Vol. 288 (20) , 6019-6034
The structural mechanism for the nucleoside tri‐ and diphosphate hydrolysis activity of Ntdp from Staphylococcus aureus
Staphylococcus aureus is a well‐known clinical pathogenic bacterium. In recent years, due to the emergence of multiple drug‐resistant strains of S. aureus in clinical practice, S. aureus infections have become an increasingly severe clinical problem. Ntdp (nucleoside tri‐ and diphosphatase, also known as Sa1684) is a nucleotide phosphatase that has a significant effect on the proliferation of S. aureus colonies and the killing ability of the host. Here, we identified the nucleoside tri‐ and diphosphate hydrolysis activity of Ntdp and obtained the three‐dimensional structures of apo‐Ntdp and three substrate analog (ATPγS, GDPβS, and GTPγS) complexes of Ntdp. Through structural analysis and biochemical verification, we illustrated the structural basis for the divalent cation selectivity, substrate recognition model, and catalytic mechanism of Ntdp. We also revealed a possible basal functional pattern of the DUF402 domain and hypothesized the potential pathways by which the protein regulates the expression of the two‐component regulatory factor agr and the downstream virulence factors. Overall, the above findings provide crucial insights into our understanding of the Ntdp functional mechanism in the infection process.
- 6 May 2021
- Published by Wiley in The FEBS Journal
- Vol. 288 (20) , 6019-6034
Open AccessThe structural mechanism for the nucleoside tri‐ and diphosphate hydrolysis activity of Ntdp from Staphylococcus aureus
Staphylococcus aureus is a well‐known clinical pathogenic bacterium. In recent years, due to the emergence of multiple drug‐resistant strains of S. aureus in clinical practice, S. aureus infections have become an increasingly severe clinical problem. Ntdp (nucleoside tri‐ and diphosphatase, also known as Sa1684) is a nucleotide phosphatase that has a significant effect on the proliferation of S. aureus colonies and the killing ability of the host. Here, we identified the nucleoside tri‐ and diphosphate hydrolysis activity of Ntdp and obtained the three‐dimensional structures of apo‐Ntdp and three substrate analog (ATPγS, GDPβS, and GTPγS) complexes of Ntdp. Through structural analysis and biochemical verification, we illustrated the structural basis for the divalent cation selectivity, substrate recognition model, and catalytic mechanism of Ntdp. We also revealed a possible basal functional pattern of the DUF402 domain and hypothesized the potential pathways by which the protein regulates the expression of the two‐component regulatory factor agr and the downstream virulence factors. Overall, the above findings provide crucial insights into our understanding of the Ntdp functional mechanism in the infection process.
- Open Access
- 1 December 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (51) , 17865-17876
Antibiotic binding releases autoinhibition of the TipA multidrug-resistance transcriptional regulator
- 1 December 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (51) , 17865-17876
Open AccessAntibiotic binding releases autoinhibition of the TipA multidrug-resistance transcriptional regulator